Publication Year

Rish W. 2010. Practical aspects of risk assessment for Brownfield development. Chapter 25 in Davis T (ed.), Brownfields, Third Edition. American Bar Association.

Olchanski N, Slawsky KA, Plent S, Kado C, Cyr PL. 2010. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a U.S. hospital. Hosp Prac 38(4):138-146; doi: 10.3810/hp.2010.11.351.

Chernoff N, Rogers JM. 2010. Hypoxia and the edema syndrome: Elucidation of a mechanism of teratogenesis. Birth Defects Res B 89(4):300–303; doi: 10.1002/bdrb.20258.

Shepard TH, Barr M Jr, Brent RL, Hendrickx A, Kochhar D, Oakley G, Scott WJ Jr, Rogers JM. 2010. An updated history of the Teratology Society. Birth Defects Res A 88(5):263–285; doi: 10.1002/bdra.20669.

Tachovsky JA, Urban JD, Wikoff DS, Haws LC, Harris MA. 2010. Reduction of a large fish tissue analyte database: Identifying and assessing data specific to a remediation site for risk assessment application. Chemosphere 80(5):481-488; doi: 10.1016/j.chemosphere.2010.04.072.

Tachovsky JA, Haws L. Application of principal components analysis and sequential gaussian simulation to a comprehensive soil sampling dataset to predict PCDD/F concentrations in Midland, MI. Presented at Dioxin 2010, San Antonio, TX, September 2010.

Racz L, Datta T, Goel RK. 2010. Organic carbon effect on nitrifying bacteria in a mixed culture. Water Sci Technol 61(11):2951–2956; doi: 10.2166/wst.2010.061.

Racz L, Goel RK. 2010. Fate and removal of estrogens from municipal wastewater. J Environ Monit 12(1):58–70; doi: 10.1039/b917298j.

Racz L, Datta T, Goel RK. 2010. Effect of organic carbon on ammonia oxidizing bacteria in a mixed culture. Bioresource Technol 101(16):6454–6460; doi: 10.1016/j.biortech.2010.03.058.

Covington T, Jakubowski E, McGuire J, Byers C, Evans R, Hulet S, Whalley C, Lumley L, Clarkson E, Gearhart J. A multi-species and -route, ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Poster presented at the Bioscience Review Conference, Baltimore, MD, May 2010.

Daston GP, Chapin R, Scialli AR, Piersma AH, Carney EW, Rogers JM, Friedman JM. 2010. A different approach to validating screening assays for developmental toxicity. Birth Defects Res B 89(6):526–530. doi: 10.1002/bdrb.20276.

Waters MD, Jackson MA, Lea IA. 2010. Characterizing and predicting carcinogenicity and mode-of-action using conventional and toxicogenomics methods. Mutat Res 705(3):184–200; doi: 10.1016/j.mrrev.2010.04.005.

Yu KO, Ruark CD, Hack CE, Sterner TR, Covington TR, Gearhart JM. A physiologically based pharmacokinetic model for pralidoxime in the guinea pig and human. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2010.

Zhao QJ, Haber L, Kohrman-Vincent M, Nance P, Dourson M. 2010. Quantitative modeling in noncancer risk assessment. In: Krishnan K, Andersen ME (eds), Quantitative modeling in toxicology. John Wiley & Sons Ltd.

Maier A, Kohrman-Vincent M, Parker A, Haber LT. 2010. Evaluation of concentration-response options for diacetyl in support of occupational risk assessment. Regul Toxicol Pharmacol 58(2):285–296; doi: 10.1016/j.yrtph.2010.06.011.

Dourson M, Kohrman-Vincent M, Allen B, Cain W. 2010. Dose response assessment from effects of acute exposure to methyl isothiocyanate (MITC). Regul Toxicol Pharmacol 58(2):181–188; doi: 10.1016/j.yrtph.2010.04.006.

Cain WS, Dourson ML, Kohrman-Vincent MJ, Allen BC. 2010. Human chemosensory perception of methyl isothiocyanate: Odor and chemesthesis. Regul Toxicol Pharmacol 58(2):173–180; doi: 10.1016/j.yrtph.2010.06.018.

Thompson CM, Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3; doi: 10.1016/j.toxlet.2009.11.023.

Tachovsky A, Staskal D, Urban J, Harris MA, Haws L. 2010. Assessment of environmental data collected in a community with numerous petroleum refining and petrochemical facilities. Presented at 49th Annual Meeting of Society of Toxicology, Salt Lake City, Utah, March 2010.

Xue C-B, Chen L, Cao G, … Keller D, et al. 2010. Discovery of INCB9471, a potent, selective, and orally bioavailable CCR5 antagonist with potent anti-HIV-1 activity. ACS Med Chem Lett 1(9):483–487, doi: 10.1021/ml1001536.